The modern approach to the correction of menopausal disorders in women with physiological menopause and after ovariectomy by Henyk, Nataliya et al.
Galician medical journal 2017
Vol. 24, Issue 2, E201728
DOI: 10.21802/gmj.2017.2.8
Research Article
The modern approach to the correction of
menopausal disorders in women with physiological
menopause and after ovariectomy
Nataliya Henyk, Lyudmyla Hinchytska, Igor Levytskyi, Olga Neiko, Ruslana Gotsaniuk*
Abstract
The problem of menopause attracts attention for many decades of not only gynecologists, but urologists, cardiologists,
psychiatrists and other doctors. This is related to systemic complications of estrogen deficiency.
The objective of our work is to establish clinical and hormonal changes in women of menopausal age with physiological
menopause and after ovariectomy and also assess the effectiveness of the offered treatment. During the examination and
treatment the women were divided as follows: I – main group – 48 women with physiological menopause: Ia (n=27) – within
three months received a complex of non-hormonal treatment, Ib (n=21) – hormone replacement therapy (HRT); II group
– 34 women after total ovariectomy: IIa (16) with therapeutic purpose received a complex of non-hormonal treatment for
three months, IIb (18) – HRT. The offered complex of non-hormonal treatment included Cimicifuga, Menopace, Noophen.
This treatment was used in women with early menopause who have contraindications to HRT or refused to take hormones.
The degree of severity of menopausal syndrome was judged according to the menopausal index of Kuperman. In the study
of hormonal status the determination of a set of hormones by immunochemical method was performed. During study we
obtained results that indicate the inverse dynamics of menopausal disorders in both study groups. For the prevention and
treatment of individual selection of treatment of climax manifestations it is appropriate the dynamic definition of hormonal
mirrors of the patients.
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Problem statement and analysis of the
recent research
The problem of menopause for many decades attracts attention
not only of gynecologists but also of urologists, cardiologists,
psychiatrists and other doctors. This is due to systemic com-
plications of estrogen deficiency [1,3,4]. For a long time the
hypothesis of the beginning of menopause due to changes in
primary hypothalamic centers with their reduced sensitivity to
estrogens and inadequate increase of pituitary gonadotropins
has dominated (follicular-stimulating (FSH) and luteinizing
(LH) hormones). Now the hypothesis of a primary deficiency
of inhibin products by aging ovaries dominates. Its decline
causes increase of FSH and then of LH [1-4,12]. That is, the
levels of FSH and inhibin are inversely proportional ratios,
that leads to anovulatory cycles and in future to complete
follicular atresia [2-4].
Already during the premenopause, ovaries are less respon-
sive to pituitary gonadotropins and reduce the secretion of
estrogens and progestogens (the degree of estradiol levels re-
duction in blood reaches 90.0%). At the same time the level of
androgen such as androstenedione reduces by half, but testos-
terone concentration decreases slightly. As a result, against
the backdrop of estrogens’ deficiency various clinical mani-
festations in the form of disease states develop in menopause.
Often they are of pronounced character that serves as the basis
for their allocation into a separate nosological form – climac-
teric syndrome (CS), which is manifested by neurovegeta-
tive (NVS), psycho-emotional (PES) and metabolic-endocrine
(EMS) symptomatic complexes [4,5]. A woman spends in
menopause almost a third of life, so the goal of treatment is
not only leveling of the symptoms of menopausal syndrome,
but also the prevention of atherosclerosis, urogenital disorders,
osteoporosis.
Most pathogenetically reasonable method of treatment,
which is aimed at the key mechanisms of menopausal com-
plications, is hormone replacement therapy (HRT), which
is widely used around the world [1,5,6,7]. If there are any
contraindications to the use of hormone replacement therapy
(cancer of the uterus and breasts, uterine bleedings of un-
explained genesis, acute thrombophlebitis, thromboembolic
disorders associated with estrogens intake, renal and liver
failure, porphyria, meningioma and others [1,3,9]) as an al-
ternative they use phytoestrogens – the non-steroidal plant
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molecules possessing estrogen, anti-inflammatory, antioxidant
and anti-cancer activity [2,8,10].
The objective of the work. To determine the clinical and
hormonal changes in women of menopausal age with physio-
logical menopause before and after ovariectomy. To evaluate
the effectiveness of the offered treatment.
1. Materials and methods
Study was begun collecting complaints from time to review
and after treatment, and then performed the gynecological
examination by the conventional scheme. During examination
and treatment, women were divided as follows: I – the main
group – 48 women with physiological menopause: Ia (n=27)
– within three months received a complex of non-hormonal
treatment, Ib (n=21) – HRT; II group – 34 women after total
ovariectomy: IIa (16) with therapeutic purposes received a
complex of non-hormonal treatment for three months, IIb (18)
– HRT.
The offered complex of non-hormonal treatment included
Cimicifuga, Menopace, Noophen. This treatment was used in
women with early menopause who had contraindications to
HRT or refused to take hormones because of possible side ef-
fects [11]. Cimicifugaracemosa or bugbane clustering (Black
cohosh) belongs to a class of phytohormones. Chemical com-
ponents are a number of triterpenoids, derivatives of cinnamic
acid and esters of inosine and fuknin acids. It has estrogen
effect, as evidenced by lower level of luteinizing hormone
[8], but Cimicifuga unlike phytoestrogens (isoflavones, lig-
ands, kumestans) does not bind to estrogen receptors α and
β [10,13]. Several biological properties of Cimicifuga allow
us to consider it as phyto-selective modulators of estrogen
receptors. While the effect of phytoestrogens is several hun-
dred times lower than 17- β estradiol [8]. Noofen is used
as anti-hypoxant and as anti-anamnestic means. It has tran-
quilizer properties, reduces the severity of cognitive disor-
ders, manifestations of anxiety and fear, normalizes sleep,
improves physical and mental performance, anticonvulsant
property. Menopace is anti-menopause complex of twenty-
two vitamins, minerals and bioactive substances that weaken
the symptoms of menopause.
The degree of menopausal syndrome severity was judged
by the menopausal Kuperman index modified by E. Uvarova
[1,6]. Each symptom was assessed by the level of severity
from 0 to 3 points, after which the total amount of points
determined the level of severity of menopausal syndrome. In
the study of hormonal status, the determination of several
hormones by immunochemical method of electrochemilumi-
nescent detection (ECLICA) using test kits Roche Diagnostics
(Switzerland) and analyzer “Cobas 6000” was performed.
2. Results
General clinical study was conducted under the standard
scheme, which provides clarification of the complaints at
the moment of examination, anamnesis and also objective
therapeutic and gynecological examination.
It is known that Cimicifuga effectively reduces hot flashes
(at the level of mesolimbic system), has hypotensive action,
normalizes psycho-emotional background. Cimicifuga dopamin-
ergic effect via dopamine (D2) receptors and its serotonergic
activity reduces the frequency and intensity of hot flashes,
causes anti-depressant effect and has a pronounced positive
effect on sleep, reduction of dryness in vagina, positive ef-
fect on trophism of urinary bladder and muscular-articular
symptoms [13]. Cimicifuga also leads to the increase of the
activity of bone specifical alkaline phosphatase, indicating
the activity of osteoblasts and hence to bone-protective ef-
fect [8,10]. The positive impact of the offered complex of
treatment is confirmed by the assessment of clinical manifes-
tations and post-ovariectomy syndrome (POS) and physiolog-
ical menopause according to menopausal index uniting all
above-studied symptom-complexes (Table 1).
After our treatment the percentage of women with climac-
teric disorders of moderate level of severity decreased in Ia
group from 70.4% to 11.1%, in IIa – from 75.0% to 31.3%,
while using HRT in Ib – from 61.9% to 19%, and in IIb – from
72.2% to 27.8%. Somewhat higher rates during physiologi-
cal menopause after the use of hormonal treatment (19.0%)
as opposed to the Ia group (11.1%) are due to the fact that
before the treatment this group included women with severe
menopause. We can see a high therapeutic effect of combi-
nation of medicines such as Klimactoplan, Menopace and
Noophen to arresting of menopausal symptoms of mild and
moderate levels of severity, both in physiological and surgical
menopause within a relatively short time. Taking into account
the importance of relationship between central and peripheral
unit of pituitary-ovarian system, we performed a study of the
concentration of estradiol and follicle-stimulating hormone
in the blood serum of women from the studied groups. Data
collected during the study are represented in Table 2.
As it is seen from the above-given data represented in the
table, in women after the treatment the concentration of estra-
diol in blood serum increased from 19.03±3.29 to 22.12±3.35
in the main group and from 12.08±1.94 to 15.27±2.39 in the
comparison group. Indexes of FSH after three months of the
performed therapy decreased at almost 18% in both groups.
—————————–
3. Conclusions
During the study we have obtained the results that indicate
the reversal dynamics of menopausal disorders in both study
groups. The use of our proposed complex: Klimaktoplan,
Menopace and Noophen have significant advantages of the
influence (minimum of side effects) on the body over HRT.
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Table 1. Dynamics of modified menopausal index according to the severity of the clinical course on women of studied groups
MMI
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before after before after before after before after
treatment treatment treatment treatment treatment treatment treatment treatment
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severe 0 0 0 0 3 14.3 0 0 0 0 0 0 4 22.2 0 0
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